| PSP001 received Safe-to-proceed Letter by FDA |
| Date:2021-02-05 17:17:14 | Visits： |
| Prev:PSP001 (PEGIL29 Chimera) IND submission (FDA) Next:Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US |
Beijing Headquarter:
Add: A302 No.5 Kaituo Road, Haidian District, Beijing, China, 100085
Tel: +86-10-62975234
Manufacturing Facility & Laboratory:
Building No. 3, Peptide Valley, GuAn, Hebei, China
US Clinical Center:
Seattle, WA, USA
Copyright 2021 prositsole All Rights Reserved. 备案号：京ICP备19006758号-2